Literature DB >> 6182100

Neutralization of lymphocyte immortalization by different strains of Epstein-Barr virus with a murine monoclonal antibody.

G Miller, L Heston, G Hoffman.   

Abstract

A murine monoclonal antibody was raised against the B95-8 strain of Epstein-Barr virus (EBV), which was isolated from a case of mononucleosis after blood transfusion (Hoffman et al. Proc. Natl. Acad. Sci. U.S.A. 77:2979, 1980). We provide evidence that neutralization of immortalization by this monoclonal antibody is virus specific, since its potency was inversely related to the dose of challenge virus. Furthermore, the monoclonal antibody recognized antigens on viruses grown in human as well as in marmoset cells. We show that this monoclonal antibody neutralized three other transforming strains of EBV originating, respectively, from American patients with mononucleosis and fatal polyclonal lymphoma and from an African child with Burkitt lymphoma. However the antibody did not neutralize or detect antigens by immunofluorescence in the W91 strain of EBV. The hybridoma antibody did neutralize other EBV strains derived from the same Burkitt lymphoma cell line (Nyevu), as was the case with the W91 strain. This monoclonal antibody provides clear evidence of antigenic differences on the surface of EBVs and will ultimately prove useful in defining the antigenic site on EBV which elicits neutralizing antibody.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6182100      PMCID: PMC347642          DOI: 10.1128/iai.37.3.1028-1031.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  12 in total

1.  Comparison between two antibody populations in the EBV system: anti-MA versus neutralizing antibody activity.

Authors:  A de Schryver; A Rosén; P Gunvén; G Klein
Journal:  Int J Cancer       Date:  1976-01-15       Impact factor: 7.396

2.  Cross-neutralization of infectious mononucleosis and Burkitt lymphoma strains of Epstein-Barr virus with hyperimmune rabbit antisera.

Authors:  D Coope; L Heston; J Brandsma; G Miller
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

3.  Characterization of cross-reacting antigens on the Epstein-Barr virus envelope and plasma membranes of producer cells.

Authors:  D A Thorley-Lawson
Journal:  Cell       Date:  1979-01       Impact factor: 41.582

4.  Antigenic differences between the membrane antigen polypeptides determined by different EB virus isolates.

Authors:  S M Franklin; J R North; A J Morgan; M A Epstein
Journal:  J Gen Virol       Date:  1981-04       Impact factor: 3.891

5.  Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.

Authors:  D A Thorley-Lawson; K Geilinger
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

6.  Diffuse polyclonal B-cell lymphoma during primary infection with Epstein-Barr virus.

Authors:  J E Robinson; N Brown; W Andiman; K Halliday; U Francke; M F Robert; M Andersson-Anvret; D Horstmann; G Miller
Journal:  N Engl J Med       Date:  1980-06-05       Impact factor: 91.245

7.  Radioimmune precipitation study comparing the Epstein-Barr virus membrane antigens expressed on P3HR-1 virus-superinfected Raji cells to those expressed on cells in a B-95 virus-transformed producer culture activated with tumor-promoting agent (TPA).

Authors:  L F Qualtiere; G R Pearson
Journal:  Virology       Date:  1980-04-30       Impact factor: 3.616

8.  Biological properties and viral surface antigens of Burkitt lymphoma- and mononucleosis- derived strains of Epstein-Barr virus released from transformed marmoset cells.

Authors:  G Miller; D Coope; J Niederman; J Pagano
Journal:  J Virol       Date:  1976-06       Impact factor: 5.103

9.  Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.

Authors:  G J Hoffman; S G Lazarowitz; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

10.  Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.

Authors:  G Miller; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-01       Impact factor: 11.205

View more
  8 in total

1.  Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.

Authors:  T Sairenji; G Bertoni; M M Medveczky; P G Medveczky; Q V Nguyen; R E Humphreys
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

2.  Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.

Authors:  Jerome E Tanner; Mathieu Coinçon; Valérie Leblond; Jing Hu; Janey M Fang; Jurgen Sygusch; Caroline Alfieri
Journal:  J Virol       Date:  2015-02-18       Impact factor: 5.103

3.  Mitosis-specific hyperphosphorylation of Epstein-Barr virus nuclear antigen 2 suppresses its function.

Authors:  Wei Yue; Matthew G Davenport; Julia Shackelford; Joseph S Pagano
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

4.  Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay.

Authors:  Junji Sashihara; Peter D Burbelo; Barbara Savoldo; Theodore C Pierson; Jeffrey I Cohen
Journal:  Virology       Date:  2009-07-07       Impact factor: 3.616

5.  Antibody evasion by a gammaherpesvirus O-glycan shield.

Authors:  Bénédicte Machiels; Céline Lété; Antoine Guillaume; Jan Mast; Philip G Stevenson; Alain Vanderplasschen; Laurent Gillet
Journal:  PLoS Pathog       Date:  2011-11-17       Impact factor: 6.823

6.  Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a 200,000 dalton EBV membrane antigen.

Authors:  T Sairenji; P S Reisert; R C Spiro; T Connolly; R E Humphreys
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

7.  Construction and Characterization of a Humanized Anti-Epstein-Barr Virus gp350 Antibody with Neutralizing Activity in Cell Culture.

Authors:  Jerome E Tanner; Jing Hu; Caroline Alfieri
Journal:  Cancers (Basel)       Date:  2018-04-09       Impact factor: 6.639

8.  A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.

Authors:  Xiao Zhang; Bingchun Zhao; Mingmei Ding; Shuo Song; Yinfeng Kang; Yang Yu; Miao Xu; Tong Xiang; Ling Gao; Qisheng Feng; Qinjian Zhao; Mu-Sheng Zeng; Claude Krummenacher; Yi-Xin Zeng
Journal:  Theranostics       Date:  2020-04-27       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.